Accretion Nutraveda Ltd reported a strong H1 FY27 performance with revenue jumping 109% YoY to Rs 29.44 crore. While absolute profit rose nearly 99% to Rs 4.73 crore, the company faced some margin compression, with EBITDA margins contracting to 21.27%. The company plans to scale manufacturing through new leasing and automation to support its growing Ayurvedic and nutraceutical segments.
Accretion Nutraveda Reports Robust H1 FY27 Growth
Revenue reached Rs 29.44 crore; PAT stood at Rs 4.73 crore.
Reader Takeaway: Strong top-line growth driven by wellness demand, though operational scaling is currently pressuring net profit margins.
What just happened
Accretion Nutraveda Ltd released its financial performance for the first half of fiscal year 2027. The company recorded a significant increase in revenue, rising 109.35% to Rs 29.44 crore from Rs 14.06 crore in the same period last year. Profit after tax (PAT) also saw a substantial gain of 98.66%, reaching Rs 4.73 crore.
Why this matters
The results highlight the company's aggressive scaling post-listing in February 2026. By doubling its top-line, the firm has demonstrated strong market traction for its Ayurvedic and nutraceutical offerings. However, the company witnessed margin compression, with EBITDA margins narrowing by 241 basis points to 21.27%, indicating that input or operational costs are rising alongside the expansion.
Strategic Growth and Capex
Management has outlined a clear path for expansion. The company intends to lease additional facilities adjacent to its current site to increase production capacity. Furthermore, the firm is investing in machinery and automation to improve efficiency. These efforts are part of a broader strategy to diversify its product portfolio and expand its international footprint via new distribution partnerships.
Risks to watch
Investors should monitor the company's ability to stabilize margins. As the company invests in capex and scales its infrastructure, any delay in operational efficiency gains could lead to continued pressure on profitability. Additionally, the company's reliance on international registrations and distribution partnerships remains a variable factor for growth.
Context metrics
As of September 30, 2026, the promoter group holds a 73.48% stake in the company, with public shareholders holding the remaining 26.52%. The company operates across three verticals: CDMO services, own-brand exports, and product licensing.